WebHey all! An update from me as we ring in the new year: last week was my last at CBS News after more than three years. It was an honor and privilege working... 23 comments on LinkedIn Web14 apr. 2024 · Acelyrin, with 3 late-phase trials underway, seeks IPO boost to $400M VC haul to take on Lilly, Novartis. Exelixis accepts Farallon's board suggestions, but dispute wages on toward proxy fight. FDA rejects Eli Lilly's ulcerative colitis prospect mirikizumab, citing manufacturing shortfallsrejects Eli Lilly's ulcerative colitis prospect
Articles by Max Bayer’s Profile Fierce Biotech Journalist Muck Rack
WebMax Bayer is a staff writer for Fierce Biotech. He joined after more than three years at CBS News, two of which were spent covering the twists and turns of the COVID-19 pandemic, … WebMax Bayer is a staff writer for Fierce Biotech. He joined after more than three years at CBS News, two of which were spent covering the twists and turns of the COVID-19 pandemic, from infection trends to CDC guidelines. He graduated from the University of Wisconsin-Madison in 2024 and moved to New York City shortly thereafter. genteq 5kcp39mfac15as
04.14.23 IPO route catches 2 biotechs; Lilly gets FDA no for ...
WebNEWS! GTP Bioways, a leading contract development and manufacturing organisation (CDMO) for biologics, extends its existing capabilities through the opening of… Web28 mrt. 2024 · ACC: Bayer and Merck’s vericiguat leads off virtual meeting with positive phase 3 heart failure data – FierceBiotech Posted: March 28, 2024 at 5:49 pm After teasing positive top-line results last November, a deeper dive into Merck & Co. and Bayers heart failure drug vericiguat helped kick off this years scientific meeting of the American … WebEvery business day, FierceBiotech and its family of publications covers the waterfront in drug development and MedTech, from pre-clinical science to seed funding and venture … chris davies financial adviser